Viridans group streptococci in blood culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin resistance genes

International Journal of Antimicrobial Agents

Volumn 28, Issue 4, 2006, Pages 292-296

  Westling, Katarina ^a   Julander, Inger ^a   Ljungman, Per ^a   Jalal, Shah ^a   Nord, Carl Erik ^a   Wretlind, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic susceptibility testing; Dalbavancin; Daptomycin; Linezolid; Tigecycline; Viridans group streptococci

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; ERYTHROMYCIN; LINEZOLID; PENICILLIN G; TIGECYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEPTICEMIA; SWEDEN; UNIVERSITY HOSPITAL;

BLOOD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; SEPSIS; STREPTOCOCCAL INFECTIONS; SWEDEN; VIRIDANS STREPTOCOCCI;

EID: 33748756593     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.05.032     Document Type: Article

References (35)

1. Bouvet A. Invasive infections by Streptococcus viridans (oral streptococci) excluding pneumococci. Presse Med 26 (1997) 1768-1773 [in French]
2. National Registry of Infective Endocarditis. Swedish Society of Infectious Diseases; 2002.
3. Wilson W.R., Karchmer A.W., Dajani A.S., et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 274 (1995) 1706-1713
4. Bochud P.Y., Calandra T., and Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 97 (1994) 256-264
5. Tunkel A.R., and Sepkowitz K.A. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 34 (2002) 1524-1529
6. Cruciani M., Rampazzo R., Malena M., et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23 (1996) 795-805
7. Kerr K.G., Armitage H.T., and McWhinney P.H. Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. Support Care Cancer 7 (1999) 28-30
8. Durack D.T., Lukes A.S., and Bright D.K. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 96 (1994) 200-209
9. Tapp J., Thollesson M., and Herrmann B. Phylogenetic relationships and genotyping of the genus Streptococcus by sequence determination of the RNase P RNA gene, rnpB. Int J Syst Evol Microbiol 53 (2003) 1861-1871
10. Carratala J., Alcaide F., Fernandez-Sevilla A., Corbella X., Linares J., and Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 20 (1995) 1169-1173
11. Ardanuy C., Tubau F., Linares J., Dominguez M.A., Pallares R., and Martin R. Distribution of subclasses mefA and mefE of the mefA gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes. Antimicrob Agents Chemother 49 (2005) 827-829
12. Gershon A.S., de Azavedo J.C., McGeer A., et al. Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000. Antimicrob Agents Chemother 46 (2002) 1553-1556
13. Lyytikainen O., Rautio M., Carlson P., et al. Nosocomial bloodstream infections due to viridans streptococci in haematological and non-haematological patients: species distribution and antimicrobial resistance. J Antimicrob Chemother 53 (2004) 631-634
14. Levitz R.E. Prosthetic-valve endocarditis caused by penicillin-resistant Streptococcus mitis. N Engl J Med 340 (1999) 1843-1844
15. Levy C.S., Kogulan P., Gill V.J., Croxton M.B., Kane J.G., and Lucey D.R. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin Infect Dis 33 (2001) 577-579
16. Prabhu R.M., Piper K.E., Baddour L.M., Steckelberg J.M., Wilson W.R., and Patel R. Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. Antimicrob Agents Chemother 48 (2004) 4463-4465
17. Westling K., Ljungman P., Thalme A., and Julander I. Streptococcus viridans septicaemia: a comparison study in patients admitted to the departments of infectious diseases and haematology in a university hospital. Scand J Infect Dis 34 (2002) 316-319
18. Westling K., Julander I., Ljungman P., Heimdahl A., Thalme A., and Nord C.E. Reduced susceptibility to penicillin of viridans group streptococci in the oral cavity of patients with haematological disease. Clin Microbiol Infect 10 (2004) 899-903
19. Farber B.F., Eliopoulos G.M., Ward J.I., Ruoff K.L., Syriopoulou V., and Moellering Jr. R.C. Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother 24 (1983) 702-705
20. Bryskier A. Viridans group streptococci: a reservoir of resistant bacteria in oral cavities. Clin Microbiol Infect 8 (2002) 65-69
21. Smith A., Jackson M.S., and Kennedy H. Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agents. Scand J Infect Dis 36 (2004) 259-263
22. Aracil B., Minambres M., Oteo J., Torres C., Gomez-Garces J.L., and Alos J.I. High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother 48 (2001) 592-594
23. Cars O., Molstad S., and Melander A. Variation in antibiotic use in the European Union. Lancet 357 (2001) 1851-1853
24. Cruciani M. Antibacterial prophylaxis. Int J Antimicrob Agents 16 (2000) 123-125
25. Entenza J.M., Caldelari I., Glauser M.P., and Moreillon P. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. J Antimicrob Chemother 44 (1999) 775-786
26. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
27. Ng K.H., Lee S., Yip S.F., and Que T.L. A case of Streptococcus mitis endocarditis successfully treated by linezolid. Hong Kong Med J 11 (2005) 411-413
28. Zimmer S.M., Caliendo A.M., Thigpen M.C., and Somani J. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 37 (2003) e29-e30
29. Gales A.C., Sader H.S., and Jones R.N. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 11 (2005) 95-100
30. Mushtaq S., Warner M., Johnson A.P., and Livermore D.M. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J Antimicrob Chemother 54 (2004) 617-620
31. Biedenbach D.J., Beach M.L., and Jones R.N. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 40 (2001) 173-177
32. Petersen P.J., Bradford P.A., Weiss W.J., Murphy T.M., Sum P.E., and Projan S.J. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 46 (2002) 2595-2601
33. Baltz R.H., Miao V., and Wrigley S.K. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep 22 (2005) 717-741
34. Oberholzer C.M., and Caserta M.T. Antimicrobial update: daptomycin. Pediatr Infect Dis J 24 (2005) 919-920
35. Sader H.S., Fritsche T.R., Streit J.M., and Jones R.N. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003. J Chemother 17 (2005) 477-483